Polymer-Drug Conjugates as Nanotheranostic Agents

Since the last decade, polymer-drug conjugate (PDC) approach has emerged as one of most promising drug-delivery technologies owing to several benefits like circumventing premature drug release, offering controlled and targeted delivery, improving stability, safety, kinetics conjugated drugs, so forth. In recent years, PDC technology advanced with objective further enhance treatment outcomes by integrating nanotechnology multifunctional characteristics into these systems. One such development is ability PDCs act theranostic agents, permitting simultaneous diagnosis options. Theranostic nanocarriers offer opportunity track distribution within body help localize diseased site. This characteristic particular interest, especially among those therapeutic approaches where external stimuli are supposed be applied for abrupt release at target site localized delivery avoid systemic side effects (e.g., Visudyne®). Thus, this review article, we presenting updates in domain nanotheranostic agents. Different methodologies utilized design along imaging their applicability a wide range diseases, have been summarized article.